Global Blood Therapeutics (GBT) Falls on Negative Analyst Chatter

October 5, 2016 1:43 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Global Blood Therapeutics (NASDAQ: GBT) is down 7.6% Wednesday amid talk of a negative call from Favus on the stock.

Shares of GBT are higher over the last several days following a bullish call from Wells Fargo's Jim Birchenough.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Short Sales, Trader Talk

Related Entities

Wells Fargo

Add Your Comment